Prof. Dr. - University Hospital Zurich

Malcolm Kohler is responsible for the clinical aspects of science within the DBI and will assess the submitted proposals with this focus. He is Chair of Respiratory Medicine at the University of Zurich and Clinical Director of the Department of Pulmonology of the University Hospital of Zurich, Switzerland. He initiated and directs a PhD program in clinical science at the University of Zurich. His research focuses on the pathophysiology and treatment of obstructive sleep apnoea and other chronic respiratory disorders. Recently he founded the Zurich Exhalomics flagship project, a research consortium which explores the metabolome of breath with diverse real-time technologies. Professor Kohler has contributed 250 scientific articles to the field of respiratory medicine and some of this work has been acknowledged with national and international awards.  


PhD in Mechanical Engineering - The University Children’s Hospital Basel (UKBB)

Pablo ML Sinues has the chemical-analytical outlook within the DBI  Scientific Committee and will assess the submitted proposals from this perspective. Acquainted with electrospray ionization, ion mobility spectrometry and mass spectrometry, he further developed mass-spectrometric methods for the real-time analysis of trace gases. Tenure-Track Assistant Professor (Botnar Research Professorship) at the University of Basel (Dep. of Biomedical Engineering), PhD Pablo ML Sinues is one of the principal investigators of the Research Network Zurich Exhalomics, an initiative by Zurich scientists to provide technical solutions for the rapid and sensitive on-line analysis of breath. He  has co-authored +40 peer-reviewed papers on different fields from engineering to medicine,  serves on the Editorial Board of the Journal of Breath Research and holds two patents.


PhD in Fluid Mechanics and Analytical Instrumentation - Fossil Ion Technology

Guillermo Vidal-de-Miguel provides the technical and instrumental approach to the DBI Scientific Committee. Expert in the development of scientific instrumentation, he learnt about breath research while working for the Eurofighter program before joining the group of Mechanical Engineering at Yale University (USA). He currently holds a total 12 patents in SESI, IMS, and MS. Guillermo worked in close collaboration with the Thermo Fisher R&D team on the development of IMS-MS. In 2014, he joined the Org. Chem. Department at ETH-Zurich to develop a SESI for breath research. Guillermo has invented the SUPER SESI configuration and the TMIMS, which are powerful tools to analyze metabolites and proteins. These systems have attracted the interest of the scientific community,

Paul Schenker.jpg.png

Serial Investor

Paul Eduard Schenker-Bodmer is a major serial investor based in Switzerland. He is fully committed to support the development of science and health-care research. The Swiss businessman has a large expertise in the field of biotechnology, especially in diagnostics-related companies. His most relevant achievement has been successfully co-founding and investing in Prionics Corporation (Switzerland) in 1996. It was an animal health diagnostics company completely acquired by multinational firm Thermo Fisher Scientific to become its subsidiary in 2014. Later on, in 2016, Paul Schenker invested in Imedos Corp, a company currently based in Germany and pioneering the Retinal Microvessel Analysis. More recently, in 2017, he has founded, Schenker Trading (China), committed to offer advanced diagnostic tools for the early detection of various diseases. He has also a great entrepreneurship and investing experience on other fields like IT and real-estate. With his background and expert vision he will help the scientific committee of the Deep Breath Initiative (DBI) evaluating the feasibility of the submitted projects.




  • The Deep Breath Initiative arises in 2018 from the collaboration of experts from different organisations involved in breath analysis research -Malcolm Kohler, Pablo Martinez-Lozano Sinues and Guillermo Vidal-de Miguel- with the support of our partner Paul Schenker.

  • The seed of the Deep Breath Initiative are specialized groups based in Switzerland aimed at providing technical solutions for the rapid and sensitive real-time analysis of exhaled breath and bringing usable analysis into the clinic by developing cutting-edge analytical technologies.

  • They all share a vision: breath analysis holds a huge potential as a non-invasive method to assist in clinical decision making, resulting into: time-reduction in the detection of pathogens, evidence-based efficient decision making, hospitalization costs-saving...

  • For these reasons the Deep Breath Initiative aims to fund and support meaningful breath research projects to the medical and scientific community.

  • The Deep Breath Initiative is sponsored by Schenker Science and Technology, Fossil Ion Technology, with the collaboration of the University Hospital of Zurich, and the Children University Hospital of Basel.